| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_924cf1586a35e1cfd46e0f70afc76882 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-008 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02C7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02C7-047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-008 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G02C7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007 |
| filingDate |
2017-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69d2bc92d89ff395ec70078201726c46 |
| publicationDate |
2018-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9931382-B2 |
| titleOfInvention |
Treatment of ophthalmic conditions |
| abstract |
Ophthalmic conditions such as presbyopia, myopia, and astigmatism can be corrected by the use of a molding contact lens in combination with a pharmaceutical composition suitable for delivery to the eye. The molding contact lenses are preferably commercially available and are not specifically designed for orthokeratology. The agents in the pharmaceutical compositions such as hyaluronase allow the cornea of the eye to be molded in order to correct the refractive error of the eye. The contact lenses and the pharmaceutical composition induce a change in the radius of curvature of the anterior surface of the cornea, thereby correcting the refractive error of the eye. One advantage of the inventive technique is that the patient with his or her own individual visual needs guides the treatment until the patient near and far visual needs are met. The present invention also provides for kits, which contain molding contact lenses, pharmaceutical composition suitable for delivery to the eye, and instructions, useful in the inventive system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10969609-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10254564-B2 |
| priorityDate |
2003-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |